NCT02299999: SAFIR02_Breast – Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

NCT02299999
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+, AR+
Other Mutations: mTOR, FGFR, EGFR, AKT, MEK, VEGFR
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Immunotherapy, Misc Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Spinal cord compression and/or symptomatic or progressive brain metastases; Bone metastases when this is the only site of biopsiable disease
https://ClinicalTrials.gov/show/NCT02299999

Comments are closed.

Up ↑